BMO Capital Starts Regeneron Pharma (REGN) at Market Perform

BMO Capital initiates coverage on Regeneron Pharma (NASDAQ: REGN) with a Market Perform rating and a price target of $419.00, suggesting 13% upside.

Analyst Matthew Luchini commented, "Our Market Perform rating is based on our anticipation for slower growth for anchor franchise Eylea, continued overhang due to Praluent litigation and Eylea Part B regulatory risk, as well as high commercial expectations for key pipeline drugs Dupixent (dupilumab) and sarilumab already being reflected in shares. We would look to get more constructive on REGN once we have visibility into the Praluent litigation (which we estimate could have 3-10% impact on our DCF) and upon confirmation that currently approved and key pipeline drugs can meet Street expectations."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $371.75 yesterday.

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $1,030 at TD Cowen
• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
• Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO